Evidence map›Paper›PMID 39135206›Full record

ArticleStem cell research & therapy2024

Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34

Farhoodeh Ghaedrahmati, Vajihe Akbari, Hooria Seyedhosseini-Ghaheh, Nafiseh Esmaeil

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Farhoodeh GhaedrahmatiDepartment of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, 81744, Iran.
Vajihe AkbariDepartment of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Hooria Seyedhosseini-GhahehNutrition and Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Nafiseh EsmaeilDepartment of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, 81744, Iran. nafesm5@gmail.com.ORCID 0000-0001-7237-1984

Funding

Isfahan University of Medical Sciences 1400182
6 · The paper itself

Abstract

backgroundUsing natural killer (NK) cells to treat hematopoietic and solid tumors has great promise. Despite their availability from peripheral blood and cord blood, stem cell-derived NK cells provide an "off-the-shelf" solution.

methodsIn this study, we developed two CAR-NK cells targeting PD-L1 derived from lentiviral transduction of human umbilical cord blood (UCB)-CD34

resultsDifferentiated CAR‑modified UCB-CD34

conclusionConsidering the more efficient transduction in stem cells and the possibility of producing CAR-NK cell products with higher yields, this approach is recommended for studies in the field of CAR-NK cells. Also, a pre-clinical study is now necessary to evaluate the safety and efficacy of these two CAR-NK cells individually and in combination with other therapeutic approaches.

Indexed as

Antigens, CD34B7-H1 AntigenFetal BloodKiller Cells, NaturalCell DifferentiationCell Line, TumorHumansImmunotherapy, AdoptiveNeoplasmsProgrammed Cell Death 1 ReceptorReceptors, Chimeric AntigenT-LymphocytesAntigens, CD34B7-H1 AntigenCD274 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Chimeric AntigenChimeric antigen receptorDifferentiationHematopoietic stem and progenitor cellsNatural killer cell

Identifiers

PMID39135206
PMCPMC11321137

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.